NO154229C - Analogifremgangsmaate ved fremstilling av antihypercholesterolemiske forbindelser. - Google Patents

Analogifremgangsmaate ved fremstilling av antihypercholesterolemiske forbindelser.

Info

Publication number
NO154229C
NO154229C NO810358A NO810358A NO154229C NO 154229 C NO154229 C NO 154229C NO 810358 A NO810358 A NO 810358A NO 810358 A NO810358 A NO 810358A NO 154229 C NO154229 C NO 154229C
Authority
NO
Norway
Prior art keywords
preparation
analogy procedure
antihypercholesterolemic compounds
antihypercholesterolemic
compounds
Prior art date
Application number
NO810358A
Other languages
English (en)
Norwegian (no)
Other versions
NO154229B (no
NO810358L (no
Inventor
Alvin K Willard
Robert L Smith
William F Hoffman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO154229(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/175,232 external-priority patent/US4293496A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO810358L publication Critical patent/NO810358L/no
Publication of NO154229B publication Critical patent/NO154229B/no
Publication of NO154229C publication Critical patent/NO154229C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
NO810358A 1980-02-04 1981-02-03 Analogifremgangsmaate ved fremstilling av antihypercholesterolemiske forbindelser. NO154229C (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11805180A 1980-02-04 1980-02-04
US11804980A 1980-02-04 1980-02-04
US17546080A 1980-08-05 1980-08-05
US06/175,232 US4293496A (en) 1980-02-04 1980-08-05 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones

Publications (3)

Publication Number Publication Date
NO810358L NO810358L (no) 1981-08-05
NO154229B NO154229B (no) 1986-05-05
NO154229C true NO154229C (no) 1986-08-13

Family

ID=27494171

Family Applications (2)

Application Number Title Priority Date Filing Date
NO810358A NO154229C (no) 1980-02-04 1981-02-03 Analogifremgangsmaate ved fremstilling av antihypercholesterolemiske forbindelser.
NO1994001C NO1994001I1 (no) 1980-02-04 1994-07-01 Simvastatin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1994001C NO1994001I1 (no) 1980-02-04 1994-07-01 Simvastatin

Country Status (22)

Country Link
EP (1) EP0033538B1 (fr)
AU (1) AU548996B2 (fr)
CA (1) CA1199322A (fr)
CY (1) CY1404A (fr)
DD (1) DD155989A5 (fr)
DE (1) DE3173042D1 (fr)
DK (1) DK157292C (fr)
ES (1) ES499079A0 (fr)
FI (1) FI78082C (fr)
GR (1) GR74798B (fr)
HK (1) HK16488A (fr)
IE (1) IE51478B1 (fr)
IL (1) IL62044A (fr)
MA (1) MA19054A1 (fr)
MY (1) MY8700745A (fr)
NL (1) NL930009I2 (fr)
NO (2) NO154229C (fr)
NZ (1) NZ196172A (fr)
PT (1) PT72441B (fr)
RO (1) RO82367B (fr)
SG (1) SG61087G (fr)
YU (1) YU28181A (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692381B2 (ja) * 1980-03-31 1994-11-16 三共株式会社 Ｍｂ−５３０ａ誘導体
US4343814A (en) * 1980-11-17 1982-08-10 Merck & Co., Inc. Hypocholesterolemic fermentation products
US4432996A (en) * 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
EP0094443A1 (fr) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S)(2,2-diméthylbutyryloxy)-2(S),6(S)-diméthyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-décahydronaphtyl-1(S))éthyl)-4(R)-hydroxy-3,4,5,6-tétrahydro-2H-pyranne-2-one, procédé de préparation et composition pharmaceutique le contenant
US4503072A (en) * 1982-12-22 1985-03-05 Merck & Co., Inc. Antihypercholesterolemic compounds
EP0117228B1 (fr) * 1983-01-24 1986-11-05 Sandoz Ag Analogues de mévalonolactone et leur dérivés, leur procédé de production, compositions pharmaceutiques les contenant ainsi que leur utilisation comme médicaments
DE3480923D1 (de) * 1983-10-11 1990-02-08 Merck & Co Inc Verfahren zur c-methylierung von 2-methylbutyraten.
EP0137444B1 (fr) * 1983-10-11 1990-01-31 Merck & Co. Inc. Procédés pour la préparation de 6(R)-(2-(8(S)(2,2-diméthylbutyryloxy)-2(S),6(S)-diméthyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-décahydronaphtyl-1(S))éthyl)-4(R)-hydroxy-3,4,5,6-tétrahydro-2H-pyran-2-one
US4668699A (en) * 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
GB8915280D0 (en) * 1989-07-04 1989-08-23 British Bio Technology Compounds
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
ES2131037T3 (es) * 1995-12-06 2001-12-16 Balkanpharma Razgrad Ad Procedimiento de preparacion de lovastatina.
CA2185961A1 (fr) 1996-09-19 1998-03-20 K.S. Keshava Murthy Methode de preparation de simvastatine
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
SI9800057A (sl) * 1998-02-26 1999-08-31 Krka, Tovarna Zdravil, D.D. Postopek za pripravo simvastatina in njegovih derivatov
CA2240983A1 (fr) 1998-06-18 1999-12-18 Yong Tao Processus de fabrication de simvastatine et de produits intermediaires
DK1140189T3 (da) 1998-12-23 2003-09-15 Searle Llc Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
BR9916486A (pt) 1998-12-23 2002-02-05 Searle Llc Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
AU2157500A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
EA004877B1 (ru) 1998-12-23 2004-08-26 Джи.Ди.Сирл Ллс Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
US6458850B1 (en) 1998-12-23 2002-10-01 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
EP1286984A2 (fr) 2000-03-10 2003-03-05 Pharmacia Corporation Procede de preparation de tetrahydrobenzothiepines
ES2329974T3 (es) * 2000-09-07 2009-12-03 Kaneka Corporation Metodos para la cristalizacion de acidos hidroxicarboxilicos.
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
SI21187A (sl) 2002-03-26 2003-10-31 Krka, Tovarna Zdravil D.D., Novo Mesto Postopek za pripravo 4-oksitetrahidropiran-2-onov
KR20040092790A (ko) * 2003-04-29 2004-11-04 씨제이 주식회사 심바스타틴 중간체 제조방법
EP1741427A1 (fr) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
PT2359826E (pt) 2006-07-05 2014-01-20 Takeda Gmbh Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
WO2009013764A2 (fr) * 2007-07-24 2009-01-29 Jubilant Organosys Limited Procédé de production du 6(r)-[2-(8'(s)-2',2'-diméthylbutyryloxy-2'(s),6'(r)-diméthyl-1,2,6,7',8',8a'(r)-hexahydronaphtyl-l'(s))éthyl]-4(r)-hydroxy-3,4,5,6-tétrahydro-2h-pyran-2-one
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
ES2343049B1 (es) 2008-10-15 2011-06-10 Neuron Biopharma, S.A. Biosintesis de derivados de monacolina j.
EP2204170A1 (fr) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Composition pharmaceutique comprenant ézétimide et simvastatine
WO2010069593A1 (fr) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Utilisation de composés amphiphiles pour la cristallisation régulée de statines et d'intermédiaires de statines
EP2327682A1 (fr) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Utilisation de composés amphiphiles pour la crystallisation controlée de statines et d'intermediaires de statines.
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
EP2241561A1 (fr) * 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Composé neuroprotecteur, hypocholestérolémiant et antiépileptique
WO2011002424A2 (fr) 2009-07-02 2011-01-06 Bilgic Mahmut Préparation pharmaceutique améliorant la solubilité et la stabilité
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2368543A1 (fr) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CA2865796A1 (fr) 2011-12-29 2013-07-04 Trustees Of Tufts College Fonctionnalisation de biomateriaux pour commander la regeneration et des reponses a une inflammation
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4049495A (en) 1974-06-07 1977-09-20 Sankyo Company Limited Physiologically active substances and fermentative process for producing the same
US4137322A (en) 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS6026094B2 (ja) 1978-07-04 1985-06-21 三共株式会社 テトラヒドロｍｌ↓−２３６ｂおよびその誘導体並びにそれを有効成分とする高脂血症治療剤
JPS5925599B2 (ja) * 1979-02-20 1984-06-19 三共株式会社 新生理活性物質モナコリンｋおよびその製造法
AU535944B2 (en) * 1979-06-15 1984-04-12 Merck & Co., Inc. Hypocholestermic fermentation products from aspergillus
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
PT72394B (en) 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics

Also Published As

Publication number Publication date
AU548996B2 (en) 1986-01-09
NO154229B (no) 1986-05-05
DE3173042D1 (en) 1986-01-09
NO810358L (no) 1981-08-05
ES8609296A1 (es) 1985-10-16
CA1199322A (fr) 1986-01-14
AU6657381A (en) 1981-08-13
RO82367A (fr) 1984-02-21
IL62044A0 (en) 1981-03-31
DD155989A5 (de) 1982-07-21
IE810204L (en) 1981-08-04
ES499079A0 (es) 1985-10-16
PT72441B (pt) 1984-08-01
IL62044A (en) 1987-03-31
FI78082C (fi) 1989-06-12
NL930009I1 (nl) 1993-04-01
NO1994001I1 (no) 1994-07-01
FI810287L (fi) 1981-08-05
PT72441A (pt) 1981-03-01
HK16488A (en) 1988-03-11
SG61087G (en) 1987-10-23
RO82367B (ro) 1984-02-28
NZ196172A (en) 1985-01-31
EP0033538A2 (fr) 1981-08-12
DK157292C (da) 1990-05-07
IE51478B1 (en) 1987-01-07
EP0033538A3 (en) 1982-02-24
CY1404A (en) 1988-04-22
DK46181A (da) 1981-08-05
DK157292B (da) 1989-12-04
FI78082B (fi) 1989-02-28
YU28181A (en) 1983-10-31
NL930009I2 (nl) 1993-09-16
GR74798B (fr) 1984-07-12
MA19054A1 (fr) 1981-10-01
EP0033538B1 (fr) 1985-11-27
MY8700745A (en) 1987-12-31

Similar Documents

Publication Publication Date Title
NO810358L (no) Fremgangsmaate ved fremstilling av antihypercholesterolemiske
NO160780C (no) Analogifremgangsmaate ved fremstilling av substituerte iminodisyrer.
NO156828B (no) Analogifremgangsmaate for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
NO812648L (no) Fremgangsmaate ved fjerning av vaeske.
NO833705L (no) Fremgangsmaate for fremstilling av fenyl-piperidin-propanol-forbindelser.
NO155699C (no) Fremgangsmaate ved fremstilling av hypocholesteremiske forbindelser.
NO159164C (no) Fremgangsmaate ved fremstilling av etylenglycol.
NO161065C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-azetidinoner.
NO159667C (no) Fremgangsmaate for fremstilling av kikhostetoksid.
NO152091C (no) Analogifremgangsmaate ved fremstilling av antiinflammatorisk virksomme 5-substituerte 2,3-difenylthiofener
NO159388C (no) Fremgangsmaate ved fremstilling av etylenbaserte kopolymerer.
NO163042C (no) Fremgangsm te ved fremstilling av stabiliserte pge2ndelser.
NO811070L (no) Fremgangsmaate ved fremstilling av ureapartikler.
NO812519L (no) Fremgangsmaate for fremstilling av kolesterase.
NO831445L (no) Fremgangsmaate for deemulgering ved hjelp av ammonium-polyamidoaminer
NO153431C (no) Fremgangsmaate ved fremstilling av 6alfa-halogen-3-keto-delta1,4-pregnadiener.
NO813814L (no) Fremgangsmaate for fremstilling av monoalkyletere av hydrokinonforbindelser
NO153258C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenyl-kinolizidiner
NO157329C (no) Analogifremgangsmaate for fremstilling av 5-fluor pgi-forbindelser.
NO162519C (no) Fremgangsmaate ved fremstilling av alkylenkarbonat.
NO812467L (no) Fremgangsmaate ved fremstilling av as-triazinderivater
NO153100C (no) Fremgangsmaate ved fremstilling av n-(halogenmethyl)-acylamider.
NO158024C (no) Fremgangsmaate ved fremstilling av propylenpolymerer.
NO158422C (no) Analogifremgangsmaate ved fremstilling av nye oksadiazolopyrimidin-derivater.
NO151933C (no) Analogifremgangsmaate ved fremstilling av antiinflammatorisk virksomme pyridoksinderivater